Literature DB >> 15635276

The effect of hormone replacement therapy on oxidized low density lipoprotein levels and paraoxonase activity in postmenopausal women.

Ata Topçuoglu1, Hafize Uzun, Seval Aydin, Nurhan Kahraman, Suphi Vehid, Gorkem Zeybek, Deniz Topçuoglu.   

Abstract

Oxidized low-density lipoproteins (oxLDL) are involved in initiation of atherosclerosis. Paraoxonase 1 (PON1), the isoenzyme of PON, is located on high-density lipoprotein (HDL) and protects against the oxidative modification of both HDL and LDL by hydrolysing lipid peroxides. Postmenopausal women have a higher risk of cardiovascular events compared with premenopausal women. The aim of this clinical study was to evaluate the effects of hormone replacement therapy (HRT) on oxLDL and PON1 activity in menopausal status. The subjects included 45 healthy postmenopausal women, aged 43 to 57 years, and 30 premenopausal women with regular cycles, aged 31 to 40 years. None of the participating women had a history of hypertension, diabetes mellitus or medications known to affect the cardiovascular system. Twenty five of the postmenopausal women received conjugated estrogens at dose of 0.625 mg/day per oral (P.O.) and medroxyprogesterone acetate (MPA) (1 mg/d P.O.) for 10 days. Twenty of the postmenopausal women received 17-beta estradiol (2 mg/day) and norethysterone acetate (NETA) (5 mg/day P.O.) for 10 days. Fasting blood samples were taken from premenopausal women (baseline) and postmenopausal women after HRT of 6 months to determine serum malondialdehyde (MDA), oxLDL, and PON1 activity. After 6-month therapy, MDA and oxLDL levels showed a statistically significant reduction in the treated groups versus baseline (p <0.05), whereas PON1 activities were increased (p <0.05). Increase in oxidative status may be one of the factors leading to reduction in PON1 activity and increased oxLDL in menopause. HRT may be effective on oxidative stress and lipoprotein metabolism in apparently healthy postmenopausal women.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15635276     DOI: 10.1620/tjem.205.79

Source DB:  PubMed          Journal:  Tohoku J Exp Med        ISSN: 0040-8727            Impact factor:   1.848


  7 in total

1.  Immunobiochemical analysis of Paraoxonase1 (anti-oxidant), xanthine oxidase (oxidant) enzymes and lipid profile of cardiac disease patients in Lahore Metropolitan, Pakistan.

Authors:  Zahoor Qadir Samra; Adeela Sana; Sadia Bano; Mariam Farooq; Nadia Dar; Muhammad Amin Athar
Journal:  J Clin Lab Anal       Date:  2010       Impact factor: 2.352

2.  Estradiol enhances cell-associated paraoxonase 1 (PON1) activity in vitro without altering PON1 expression.

Authors:  Syed Ahmad; John E Scott
Journal:  Biochem Biophys Res Commun       Date:  2010-05-27       Impact factor: 3.575

3.  Hormonal and chemical regulation of paraoxonases in mice.

Authors:  Xingguo Cheng; Curtis D Klaassen
Journal:  J Pharmacol Exp Ther       Date:  2012-05-31       Impact factor: 4.030

4.  Paraoxonase 1 polymorphisms and risk of myocardial infarction in women and men.

Authors:  Kenneth J Mukamal; Jennifer K Pai; Majken K Jensen; Eric B Rimm
Journal:  Circ J       Date:  2009-05-15       Impact factor: 2.993

5.  Effect of aerobic and anaerobic exercise on estrogen level, fat mass, and muscle mass among postmenopausal osteoporotic females.

Authors:  Zainab Abdul Razzak; Amna Aamir Khan; Sumaira Imran Farooqui
Journal:  Int J Health Sci (Qassim)       Date:  2019 Jul-Aug

6.  Grape polyphenols increase the activity of HDL enzymes in old and obese rats.

Authors:  Andriy L Zagayko; Ganna B Kravchenko; Oksana A Krasilnikova; Yuri O Ogai
Journal:  Oxid Med Cell Longev       Date:  2013-07-14       Impact factor: 6.543

7.  Paraoxonase 1 activity and phenotype distribution in premenopausal and postmenopausal women.

Authors:  Dražan Butorac; Ivana Celap; Sanja Kačkov; Vera Robić; Tomislav Miletić; Zlata Flegar Meštrić; Andrea Hulina; Krunoslav Kuna; Tihana Žanić Grubišić; Marija Grdić Rajković
Journal:  Biochem Med (Zagreb)       Date:  2014-06-15       Impact factor: 2.313

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.